Cash Is King in Biotech M&A, but Will Clinical Data Be a Saving Grace?
Troutman Pepper attorney Christopher Miller recently authored Reuters Legal News article " Cash Is King in Biotech M&A, but Will Clinical Data Be a Saving Grace?" where he discusses strategic considerations for biotech companies entering into M&A transactions based on recent market trends.